One-item Scale Is Reliable Tool to Assess Fatigue in Parkinson’s Patients, Study Finds
The one-item Fatigue Visual Analog Scale (VAFS) is a highly consistent and reliable tool to assess fatigue in patients with…
Articles by Marta Figueiredo, PhD
UK Experts Outline Practical Ways to Manage Wearing-off in Parkinson’s
A panel of United Kingdom-based experts has defined a set of practical considerations to manage motor fluctuations and wearing-off in…
Deep Brain Stimulation May Increase Levels of Inflammatory Factors in Parkinson’s, Study Suggests
Deep brain stimulation (DBS) may increase the levels of hepcidin — a hormone associated with iron accumulation and inflammation…
Type 2 Diabetes Seen to Raise Person’s Risk of Parkinson’s Disease in Large UK Study
Type 2 diabetes increases the risk of developing Parkinson’s disease by nearly a third, according to a large retrospective…
Researchers Identify New Gene Associated with Parkinson’s Disease, Dementia
Mutations in the LRP10 gene are associated with the development of neurodegenerative diseases with Lewy bodies formation, such as…
Dual-Target Compounds Could Lead to Single and More Effective Therapy for Parkinson’s, Study Reports
Pharmacologic compounds that can act on two target molecules show promise as potential therapies for Parkinson’s disease, according to a…
Early Symptoms May Predict Future Psychosis in Parkinson’s Patients, Study Finds
Early sleep-related and autonomic symptoms — related to automatic or involuntary body functions — are associated with an increased risk…
Potential Parkinson’s Vaccine, Affitope PD01A, Safe and Possibly Effective in Long-term, Phase 1 Trial Series Finds
Affiris’ experimental Parkinson’s vaccine, Affitope PD01A, is safe and effectively triggers an immune response against the alpha-synuclein (aSyn) protein, data…
Parkinson’s Researchers Unravel How Toxic Alfa-synuclein Affects Memory Nerve Cells
Scientists are closer to understanding how toxic alpha-synuclein (α-syn) aggregates affect the nerve cells involved in memory, which may point…
Alnylam’s RNAi Therapy for Parkinson’s Disease Fares Well in Rat Model
Alnylam’s small RNA interference (RNAi) therapies were delivered successfully to the brain and spinal cord of a rat model, bringing promise…